Outcomes of patients on dual-boosted PI regimens: experience of the Swiss HIV cohort study

Osih, Regina B; Taffé, Patrick; Rickenbach, Martin; Gayet-Ageron, Angèle; Elzi, Luigia; Fux, Christoph; Opravil, Milos; Bernasconi, Enos; Schmid, Patrick; Günthard, Huldrych F; Cavassini, Matthias; Swiss HIV Cohort Study, (2010). Outcomes of patients on dual-boosted PI regimens: experience of the Swiss HIV cohort study. AIDS research and human retroviruses, 26(11), pp. 1239-46. New York, N.Y.: Mary Ann Liebert 10.1089/aid.2010.0070

Full text not available from this repository.

Dual-boosted protease inhibitors (DBPI) are an option for salvage therapy for HIV-1 resistant patients. Patients receiving a DBPI in the Swiss HIV Cohort Study between January1996 and March 2007 were studied. Outcomes of interest were viral suppression at 24 weeks. 295 patients (72.5%) were on DBPI for over 6 months. The median duration was 2.2 years. Of 287 patients who had HIV-RNA >400?copies/ml at the start of the regimen, 184 (64.1%) were ever suppressed while on DBPI and 156 (54.4%) were suppressed within 24 weeks. The median time to suppression was 101 days (95% confidence interval 90-125 days). The median number of past regimens was 6 (IQR, 3-8). The main reasons for discontinuing the regimen were patient's wish (48.3%), treatment failure (22.5%), and toxicity (15.8%). Acquisition of HIV through intravenous drug use and the use of lopinavir in combination with saquinavir or atazanavir were associated with an increased likelihood of suppression within 6 months. Patients on DBPI are heavily treatment experienced. Viral suppression within 6 months was achieved in more than half of the patients. There may be a place for DBPI regimens in settings where more expensive alternates are not available.

Item Type:	Journal Article (Original Article)
Division/Institute:	04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Infectiology
UniBE Contributor:	Fux, Christoph Andreas
ISSN:	0889-2229
Publisher:	Mary Ann Liebert
Language:	English
Submitter:	Factscience Import
Date Deposited:	04 Oct 2013 14:13
Last Modified:	05 Dec 2022 14:02
Publisher DOI:	10.1089/aid.2010.0070
PubMed ID:	20929393
Web of Science ID:	000284311900012
URI:	https://boris.unibe.ch/id/eprint/2712 (FactScience: 205580)